Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire

Cancer

Volumn 112, Issue 10, 2008, Pages 2249-2257

  Cormier, Janice N ^a   Ross, Merrick I ^a   Gershenwald, Jeffrey E ^a   Lee, Jeffrey E ^a   Mansfield, Paul F ^a   Camacho, Luis H ^a   Kim, Kevin ^a   Webster, Kimberly ^b   Cella, David ^b   Palmer, J Lynn ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Research and Education   (United States)

Author keywords

Melanoma; Patient reported outcomes; Quality of life; Test retest reliability

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TEST RETEST RELIABILITY;

ADULT; AGED; COHORT STUDIES; EMOTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; PHYSICAL EXAMINATION; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SICKNESS IMPACT PROFILE; SKIN NEOPLASMS; SOCIAL SUPPORT; TREATMENT OUTCOME;

EID: 43049146173     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23424     Document Type: Article

References (49)

1. Coates A, Thomson D, McLeod GR, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer. 1993;29A:1731-1734.
2. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol. 1999;17:2256-2263.
3. Brandberg Y, Mansson-Brahme E, Ringborg U, Sjoden PO. Psychological reactions in patients with malignant melanoma. Eur J Cancer. 1995;31A:157-162.
4. Schofield PE, Butow PN, Thompson JF, Tattersall MH, Beeney LJ, Dunn SM. Psychological responses of patients receiving a diagnosis of cancer. Ann Oncol. 2003;14:48-56.
5. Dean GE, Spears L, Ferrell BR, Quan WD, Groshon S, Mitchell MS. Fatigue in patients with cancer receiving interferon alpha. Cancer Pract. 1995;3:164-172.
6. Cohen L, Parker PA, Sterner J, De Moor C. Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumour-derived vaccine. Melanoma Res. 2002;12:505-511.
7. Brown JE, King MT, Butow PN, Dunn SM, Coates AS. Patterns over time in quality of life, coping and psychological adjustment in late stage melanoma patients: an application of multilevel models. Qual Life Res. 2000;9:75-85.
8. Brown JE, Brown RF, Miller RM, et al. Coping with metastatic melanoma: the last year of life. Psychooncology. 2000;9:283-292.
9. Sollner W, Zingg-Schir M, Rumpold G, Mairinger G, Fritsch P. Need for supportive counselling - the professionals' versus the patients' perspective. A survey in a representative sample of 236 melanoma patients. Psychother Psychosom. 1998;67:94-104.
10. Cassileth BR, Lusk EJ, Tenaglia AN. Patients' perceptions of the cosmetic impact of melanoma resection. Plast Reconstr Surg. 1983;71:73-75.
11. Dirksen SR. Perceived well-being in malignant melanoma survivors. Oncol Nurs Forum. 1989;16:353-358.
12. Brandberg Y, Bolund C, Sigurdardottir V. Anxiety and depressive symptoms at different stages of malignant melanoma. Psychooncology. 1992;1:71-78.
13. Sollner W, Zschocke I, Zingg-Schir M, et al. Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness. Psychosomatics. 1999;40:239-250.
14. Baider L, Perry S, Sison A, Holland J, Uziely B, DeNour AK. The role of psychological variables in a group of melanoma patients. An Israeli sample. Psychosomatics. 1997;38:45-53.
15. Trask PC, Paterson AG, Hayasaka S, Dunn RL, Riba M, Johnson T. Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol. 2001;19:2844-2850.
16. Gibertini M, Reintgen DS, Baile WF. Psychosocial aspects of melanoma. Ann Plast Surg. 1992;28:17-21.
17. Cassileth BR, Lusk EJ, Tenaglia AN. A psychological comparison of patients with malignant melanoma and other dermatologic disorders. J Am Acad Dermatol. 1982;7:742-746.
18. Kelly B, Raphael B, Smithers M, et al. Psychological responses to malignant melanoma. An investigation of traumatic stress reactions to life-threatening illness. Gen Hosp Psychiatry. 1995;17:126-134.
19. Graham KY, Longman AJ. Quality of life and persons with melanoma. Preliminary model testing. Cancer Nurs. 1987;10:338-346.
20. Fawzy XW. A psychoeducational nursing intervention to enhance coping and affective state in newly diagnosed malignant melanoma patients. Cancer Nurs. 1995;18:127-438.
21. Fawzy FI, Cousins N, Fawzy NW, Kemeny ME, Elashoff R, Morton D. A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch Gen Psychiatry. 1990;47:720-725.
22. Trask PC, Paterson AC, Griffith KA, Riba MB, Schwartz JL. Cognitive-behavioral intervention for distress in patients with melanoma: comparison with standard medical care and impact on quality of life. Cancer. 2003;98:854-864.
23. Bender CM, Yasko JM, Kirkwood JM, Ryan C, Dunbar-Jacob J, Zullo T. Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res. 2000;9:352-363.
24. Sigurdardottir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncol. 1996;35:149-158.
25. Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol). 2001;13:458-465.
26. Thomson DB, Adena M, McLeod GR, et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res. 1993;3:133-138.
27. Chiarion-Sileni V, Del Bianco P, De Salvo GL, et al. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer. 2003;39:4577-4585.
28. Langenholf BS, Krabbe PF, Wobbes T, Ruers TJ. Quality of life as an outcome measure in surgical oncology. Br J Surg. 2001;88:643-652.
29. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
30. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
31. Sigurdardottir V, Bolund C, Brandberg Y, Sullivan M. The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res. 1993;2:193-203.
32. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15:974-986.
33. Cella DF, Bonomi AL, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199-220.
34. Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res. 1999;8:181-195.
35. Cormier JN, Davidson LN, Webster KA, Cella D. Development of a melanoma-specific subscale for the Functional Assessment of Cancer Therapy (FACT-Melanoma) [abstract]. 200-1 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2004;22(14S). Abstract 8122.
36. Doward LC, McKenna SP. Defining patient-reported outcomes. Value Health. 2001;7(suppl 1):S4-S8.
37. Berzon R, Hays RD, Shumaker SA. International use, application and performance of health-related quality of life instruments. Qual Life Res. 1993;2:367-368.
38. Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the Functional Assessment of Chronic Illness Therapy measurement system. Arch Phys Med Rehabil. 2002;83(12 suppl 2):S10-S17.
39. Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose, and method of measurement. Cancer Invest. 1993;11:327-336.
40. Cormier JN, Davidson L, Xing Y, Webster K, Cella D. Measuring quality of life in patients with melanoma: development of the FACT-Melanoma subscale. J Support Oncol. 2005;3:139-145.
41. Cella DF, Jacobsen PB, Orav EJ, Holland JC, Silberfarb PM, Rafla S. A brief POMs measure of distress for cancer patients. J Chronic Dis. 1987;40:939-942.
42. Crowne D, Marlowe D. A new state of social desirability independent of psychopathology. J Consult Psychol. 1960;24:349-354.
43. Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethlylene thiophosphoramide. J Chronic Dis. 1960;11:17-33.
44. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949.
45. Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Handbook. 6th ed. New York, NY: Springer-Verlag; 2002.
46. Cohen S, Underwood LG, Gottlieb BH. Social Support Measurement and Intervention. New York, NY: Oxford University Press; 2000.
47. Conover WJ. Practical Nonparametric Statistics. 3rd ed. New York, NY: John Wiley & Sons, Inc.; 1999.
48. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research: U.S. Department of Health and Human Services FDA Center fro Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes [serial online]. 2006;4:79.
49. Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006;166:1907-1944.